Back to Search
MICHELE L BASCHE MD
MD
Hematology & Oncology Physician
NPI: 1306820022IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
DR.0037127(CO)
Education
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO SCHOOL OF MEDICINE
Class of 1996
Research & Publications (13)
Treatment of non-small-cell lung cancer in older persons.
PMID 12599930·Oncology (Williston Park)·2003
6-review
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
PMID 17000682·Clin Cancer Res·2006
3-trial
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
PMID 19299492·Hum Mol Genet·2009
7-preclinical
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
PMID 18509645·Cancer Chemother Pharmacol·2009
8-other
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
PMID 18058098·Cancer Chemother Pharmacol·2008
3-trial
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
PMID 18043132·Anticancer Drugs·2008
3-trial
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
PMID 18320191·Cancer Chemother Pharmacol·2008
3-trial
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
PMID 19074845·Mol Cancer Ther·2008
3-trial
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
PMID 17693653·Ann Oncol·2007
3-trial
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
PMID 16740765·Clin Cancer Res·2006
4-observational
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
PMID 15906031·Cancer Chemother Pharmacol·2005
3-trial
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
PMID 15534096·Clin Cancer Res·2004
3-trial
Re: Tumor characteristics and clinical outcome of elderly women with breast cancer.
PMID 11136846·J Natl Cancer Inst·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1800 N WILLIAMS ST STE 200
DENVER, CO 80218 - Phone
- (303) 388-4876
Quick Facts
- NPI
- 1306820022
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 13
Are you this provider?
Claim Your Profile